ArticleExperimental animals2017
Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis).
Article in Experimental animals, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Gouty arthritis model: delving into disease pathways and uncovering possible therapeutic targets.Frontiers in endocrinology · 2026Review
- Dose-Sparing Efficacy of d-Limonene with Low-Dose Allopurinol in a Dual Model of Hyperuricemia and Gouty Arthritis in Rats.Nutrients · 2025Article
- Targeting Hyperuricemia and NLRP3 Inflammasome in Gouty Arthritis: A Preclinical Evaluation of Allopurinol and Disulfiram Combination Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Microbiome therapeutic PMC72 through reverse translational research in gout.Journal of microbiology (Seoul, Korea) · 2025Article
- Ameliorative action of "daitongxiao" against hyperuricemia includes the "uric acid transporter group".Frontiers in pharmacology · 2024Article
- Models of gouty nephropathy: exploring disease mechanisms and identifying potential therapeutic targets.Frontiers in medicine · 2024Review
- Evaluation of anti-hyperuricemic effects ofHeliyon · 2023Article
- Emodin, a Natural Anthraquinone, Increases Uric Acid Excretion in Rats with Potassium Oxonate-Induced Hyperuricemia.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia.The Journal of veterinary medical science · 2022Article
- Acute oral toxicity assessment and anti-hyperuricemic activity ofSaudi journal of biological sciences · 2022Article
- Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats.Nutrients · 2021Article
- Saengmaeksan, a traditional herbal formulation consisting ofJournal of ginseng research · 2021Article
- A brief review on in vivo models for Gouty Arthritis.Metabolism open · 2021Review
- Article
- Medicinal Plants as a Drug Alternative Source for the Antigout Therapy in Morocco.Scientifica · 2020Review
- Mouse models for human hyperuricaemia: a critical review.Nature reviews. Rheumatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Potassium oxonate, a selectively competitive uricase inhibitor, produced hyperuricemia (HUA) in rodents in a previous study. In this study, we employed the tree shrew as an animal model to study potassium oxonate-induced HUA. The effect of allopurinol (ALLO), a uric acid reducer, was also examined in this model. Potassium oxonate at doses of 5, 20, 40, 60, 80, 100, and 1,000 mg/kg was given intraperitoneally to tree shrews. The results showed that potassium oxonate can effectively increase the levels of uric acid in tree shrews at doses ranging from 40 to 100 mg/kg. Semiquantitative RT-PCR showed that the xanthine dehydrogenase/oxidase (XDH/XO) mRNA expression level was significantly higher in the liver tissue of tree shrews with high levels of uric acid. There were no changes in serum urea nitrogen, or serum creatinine values. ALLO can significantly decrease serum uric acid levels (P<0.01) and raise XDH/XO mRNA expression levels in the liver tissue of tree shrews with HUA. XDH/XO mRNA expression levels did not change in untreated tree shrews. Studies on acute toxicity in the tree shrew did not show any significantly abnormal signs. There were no adverse effects at the macroscopic level up to doses ≤100 mg/kg. Potassium oxonate induced acute HUA in tree shrews at lower doses compared with other animal models. Potassium oxonate-treated tree shrews may be a potential animal model for studying pathogenic mechanism and evaluating a new therapeutic agent for treatment of HUA in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.